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luid Retention
ith Thiazolidinediones
oes the Mechanism
nfluence the Outcome?*
oAnn Lindenfeld, MD,†
rederick A. Masoudi, MD, MSPH, FACC†‡
enver, Colorado
eart failure (HF) and diabetes mellitus (DM) are common
edical problems that are both increasing in prevalence
1,2). Diabetes mellitus is a well-known and important
ndependent risk factor for HF (3,4). Thus it is not
urprising that DM is present in nearly 20% of all patients
ospitalized for a first episode of acute decompensated HF,
n more that 25% of patients enrolled in recent clinical trials
f HF, and in 38% of Medicare beneficiaries with HF (5–9).
ny hypoglycemic agent that exacerbates HF, therefore,
epresents an important clinical problem.
See page 1696
Thiazolidinediones (TZDs) effectively improve glycemic
ontrol in patients with type 2 diabetes mellitus (T2DM)
hen used alone or in combination with other hypoglyce-
ic agents (10). The insulin-sensitizing effects of TZDs are
ediated by agonism of the peroxisome proliferator-
ctivator receptor gamma, a nuclear receptor expressed in
dipose tissue, vascular endothelium, pancreatic beta cells,
nd macrophages. In addition to improving glycemic con-
rol, TZDs have a wide range of other effects of potential
enefit in patients with HF, including the lowering of blood
ressure, improving endothelial function, improving lipids,
ecreasing circulating fatty acid levels, decreasing angioten-
in II levels, and reducing the progression of atherosclerosis
11–13). Possibly reflecting the positive view practitioners
ave of these theoretical benefits, the use of TZDs in
edicare beneficiaries hospitalized with DM and the pri-
Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.
From the †Department of Medicine, University of Colorado at Denver and Health
ciences Center, Denver, Colorado; and the ‡Department of Medicine, Denver
ealth Medical Center, Denver, Colorado. Dr. Masoudi has served on advisory
oards for Takeda NA, Amgen, and United Healthcare; has contracts with thet
klahoma Foundation for Medical Quality; and is an associate editor of Journal Watch
ardiology of the Massachusetts Medical Society.ary diagnosis of HF increased from 7.2% in 1998 to 1999
o 16.2% in 2000 to 2001 (14). Indeed, the PROactive
tudy, in which patients were randomized with known
acrovascular disease and T2DM to pioglitazone or pla-
ebo, reported a significantly lower risk of the secondary
omposite end point of death, myocardial infarction, and
troke (absolute risk reduction of 2%, hazard ratio 0.84, 95%
onfidence interval 0.72 to 0.98, p  0.027) (15). However,
he primary end point, which included both cardiovascular
nd procedural events, was not significantly reduced by
ioglitazone (absolute risk reduction of 2%, hazard ratio 
.90, 95% confidence interval 0.80 to 1.02, p  0.095),
enerating further debate about the impact of TZDs on
ardiac risk.
Thiazolidinedione therapy may also cause weight gain,
uid retention, and peripheral edema in patients and may
esult in elevations in natriuretic peptide levels—side effects
hat are of particular concern in patients with HF (11,16).
hese effects, particularly the fluid retention and edema, led
o a Consensus Statement from the American Heart Asso-
iation (AHA) and the American Diabetes Association
ADA) recommending caution in prescribing TZDs for
atients with New York Heart Association (NYHA) func-
ional class I and II HF and avoiding TZDs entirely in
atients with NYHA functional class III and IV HF (16).
luid retention and peripheral edema occur in 3% to 5% of
atients with T2DM started on TZDs and up to 15% of
atients treated with both TZDs and insulin (11,16). In
linical trials that excluded patients with a history of HF,
here were small, but sometimes significant, increases in HF
pisodes with TZDs (1%) (11,17). However, in the
ROactive study, TZD-treated patients had a 6% incidence
f HF hospitalization compared with 4% in the control
roup (p 0.007) (15). Although the number of PROactive
tudy participants with prevalent HF at enrollment was not
eported, a significant number (47%) had suffered a previous
yocardial infarction. Thus, the risk of hospitalization for
F with TZDs appears to increase as the prevalence of
ignificant underlying heart disease increases. This reported
ncrease in the risk of HF raises the question of whether the
ZDs cause myocardial depression resulting in HF, espe-
ially in patients with preexisting HF and LV dysfunction.
In this issue of the Journal, Dargie et al. (18) present the
esults of a randomized, placebo-controlled clinical trial
esigned to determine whether the TZD rosiglitazone
RSG) negatively affects myocardial function as measured
y changes in left ventricular ejection fraction (LVEF) in
ubjects with NYHA functional class I and II HF and an
VEF 45% (18). During a 52-week period, the authors
oted no significant change in LVEF or left ventricular
LV) end-diastolic or -systolic volumes in the RSG group
ompared with the control group. There were also no
ifferences in measures of diastolic function, although these
easurements were not collected in all patients, nor were
hey prespecified end points. These results confirm the
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Editorial Comment April 24, 2007:1705–7ndings of previous studies. Ghazzi et al. (19) compared LV
ass index, cardiac index, and stroke volume index in 154
ubjects with noninsulin-dependent DM randomized to
roglitazone or glyburide (19). At 24 and 48 weeks of
ollow-up, there were no significant changes in left ventric-
lar mass index in the troglitazone group, but there were
odest increases in cardiac index and stroke volume index
ostulated to be due to a decrease in peripheral vascular
esistance. St. John Sutton et al. (20) compared the effects of
SG to glyburide in subjects with normal LVEF and no
istory of HF and found no decrease in LVEF and no
ncrease in LV mass index or LV end-systolic or -diastolic
olumes with either agent over the course of 52 weeks.
ecause these studies did not specifically target subjects with
history of HF, the Dargie et al. (18) study provides
dditional reassurance that the TZDs do not cause myocar-
ial depression, even in patients with mild HF and systolic
ysfunction.
Furthermore, Dargie et al. (18) reported no increase in
efinite or possible worsening of clinical HF with RSG, but
he number of these episodes was small. The close follow-up
n this study along with the increase in HF medications also
ay have limited the number of episodes of worsening HF.
here were also considerably more cases of new or worsen-
ng edema in the RSG group (25.5% vs. 8.8%, p  0.005)
nd 32.7% of RSG-treated patients required an increase in
F medications compared with 17.5% in the control group,
ost of which were increases in diuretics. Despite the
ncrease in diuretics, there was a small, but significant,
ncrease in brain natriuretic peptide levels in the RSG
roup, suggesting a modest increase in myocardial transmu-
al pressure.
Does this study help physicians who are confronted with
patient with HF and T2DM with poor glycemic control
or whom TZD therapy might improve glycemic control?
n the basis of this study, it seems unlikely that there is a
linically significant effect of TZDs on LV systolic function.
ther mechanisms of fluid retention and edema, including
ympathetic activation, increased vascular permeability, and
he response to vasodilatation, have been suggested as
echanisms of this phenomenon (16). However, increasing
vidence in animal models suggests that the fluid retention
ith TZDs is due to sodium retention in the distal nephron
21,22). If this is the case in humans, it is undoubtedly of
mportance in a patient with or at high risk for HF,
lthough it also raises the possibility that the fluid
etention seen with TZD therapy may be treated with
iuretics that target the distal nephron (i.e., amiloride or
pironolactone) (23).
Whatever the mechanism of fluid retention, patients with
history of HF will require careful monitoring when TZDs
re initiated and, even with careful follow-up, many patients
ill apparently require either a decrease in dose or discon-
inuation of the TZD or an increase in HF medications,
specially diuretics. It is not clear, however, whether the
otential benefits of TZDs on glycemia and cardiovascular
1isk factors would be counterbalanced by the potential
etrimental effects of increased diuretic doses for controlling
dema. Retrospective studies have suggested that increasing
oses of loop diuretics may be associated with worsened
utcomes in patients with HF (24,25). These concerns are
lleviated somewhat by a retrospective study of Medicare
eneficiaries with DM and a principal discharge diagnosis
f HF that found lower overall mortality with TZD therapy
espite a higher risk of readmission for HF (26).
Thus, Dargie et al. (18) have provided important infor-
ation about the lack of a significant effect of TZDs on LV
ystolic function in subjects with HF, a history of NYHA
unctional class I and II, and LVEF 45%, but their data
lso confirm that worsening edema with the TZDs in such
atients remains an important clinical problem. Until better
ata emerge to guide the management of the fluid retention
ssociated with TZDs, the recommendations of the AHA/
DA consensus committee about the use of TZDs in
atients with HF remain relevant to the treatment of the
ncreasing number of patients with DM and HF.
eprint requests and correspondence: Dr. JoAnn Lindenfeld,
niversity of Colorado HSC, Medicine and Cardiology, 4200
ast Ninth Avenue, B-130, Denver, Colorado 80262. E-mail:
oann.lindenfeld@uchsc.edu.
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